These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
54 related articles for article (PubMed ID: 38615599)
1. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Noel GJ; Bush K; Bagchi P; Ianus J; Strauss RS Clin Infect Dis; 2008 Mar; 46(5):647-55. PubMed ID: 18225981 [TBL] [Abstract][Full Text] [Related]
2. Ceftobiprole mono-therapy versus combination or non-combination regimen of standard antibiotics for the treatment of complicated infections: A systematic review and meta-analysis. Jame W; Basgut B; Abdi A Diagn Microbiol Infect Dis; 2024 Jul; 109(3):116263. PubMed ID: 38615599 [TBL] [Abstract][Full Text] [Related]
4. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin. Anderson SD; Gums JG Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729 [TBL] [Abstract][Full Text] [Related]
5. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections. Schirmer PL; Deresinski SC Expert Rev Anti Infect Ther; 2009 Sep; 7(7):777-91. PubMed ID: 19735220 [TBL] [Abstract][Full Text] [Related]
6. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975 [TBL] [Abstract][Full Text] [Related]
7. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Barbour A; Schmidt S; Rand KH; Derendorf H Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449 [TBL] [Abstract][Full Text] [Related]